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Background: Non-adherence to medication (range 30–107%) is a major issue in patients with 
rheumatoid arthritis (RA). Previous research has shown that electronic monitoring feedback 
(EMF) might be an effective strategy to improve medication adherence in chronic conditions. 
Therefore, this study investigated the effectiveness of electronic monitoring feedback in patients 
with early RA to improve medication adherence and clinical outcomes compared to usual care.
Methods: An open-label randomized clinical trial was performed to compare EMF with 
standard care during a 12-month follow-up period on two sites of the Sint Maartenskliniek 
(Nijmegen and Boxmeer) in the Netherlands. Patients were eligible if they: (1) had 
a (working) diagnosis of early RA, (2) were currently using methotrexate, (3) were aged 
≥18 years, and (4) had a life expectancy of ≥12 months. Primary outcome was the difference 
in proportion of non-adherent patients measured with the Compliance Questionnaire on 
Rheumatology after 12 months. Secondary outcomes were beliefs about medicines, medica-
tion adherence measured with the MMAS-8®, patients' health status, prescription of biologic 
DMARDs, and disease activity after 12 months.
Results: Of the 367 initially-invited patients, 93 patients with early RA agreed to participate 
in this study. No significant difference was found in the proportion of non-adherent patients 
between the intervention arm and the usual care arm after 12 months follow-up (60.0% and 
61.3%, p=0.93, respectively). Patients in the intervention arm tended to discontinue metho-
trexate earlier than patients in the usual care arm (median time in weeks: 15.7 (9.1–33.6) and 
21.9 (19–28.4), respectively, p=0.31), whereas patients in the usual care arm tended to 
initiate biologic DMARDs earlier than those in the intervention arm (median time in 
weeks: 11.9 (5.7–22) and 17 (9.9–40.9), respectively, p=0.55).
Conclusion: This study illustrates the challenge of targeting non-adherence with EMF in 
patients with early RA and shares important lessons learned about designing adherence 
intervention trials with respect to study attrition, accounting for drug survival, intervention 
fidelity, intervention uptake, and technical aspects.
Keywords: randomized clinical trial, rheumatoid arthritis, DMARDs, medication adherence, 
disease activity, clinical outcomes
Introduction
In rheumatoid arthritis (RA), maximum treatment benefits can only be achieved 
when patients take their disease-modifying antirheumatic drugs (DMARDs).1,2 
However, previous research revealed that medication adherence to DMARDs 
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ranged from 30–107%, depending on the measurement 
methods used to assess medication-taking behavior.3–5 
Non-adherence to DMARDs is associated with higher 
disease activity scores and an increased risk of radio-
graphic damage.2,6–8 Since irreversible articular damage 
mainly occurs early in the course of RA, with most rapid 
radiologic progression during the first two years after 
diagnosis, it is likely that patients with early RA will 
benefit most from adherence-improving interventions.9,10 
Additionally, intervening in non-adherence to medication 
in the early course of RA might prevent or delay the 
initiation of the more expensive biologic DMARDs 
(bDMARDs), which has the potential to reduce healthcare 
expenditures and might possibly be cost-effective.11 
Therefore, effective interventions to improve medication 
adherence in the early course of RA are warranted.
So far, studies on adherence-improving interventions in 
patients with rheumatic diseases are limited, with studies 
often reporting inconsistent results on adherence and clin-
ical outcomes.12,13 However, electronic monitoring feed-
back (EMF) is considered to be one of the most promising 
interventions in improving adherence outcomes in adult 
patients.13–15 EMF is defined as tailored feedback (instant 
or non-instant) on electronically obtained adherence data 
to improve or sustain medication-taking behavior.13,14 
Electronic devices, such as Medication Event Monitoring 
Systems (MEMS), register time intervals between conse-
cutive openings of MEMS bottles and, therefore, provide 
insight in medication adherence patterns of patients based 
on device usage.5,14,16,17 These data can be used to (1) 
confront patients with their own medication-taking beha-
vior, and (2) support healthcare professionals in providing 
tailored and non-judgmental feedback.14 Such feedback 
includes the elicitation and strengthening of patients' 
intrinsic motivation to overcome practical and perceptual 
barriers to adequate medication intake in daily life (eg 
concerns about the prescribed medication and beliefs 
related to medication necessity), and to overcome knowl-
edge gaps regarding DMARD treatment.14 Several barriers 
to adequate medication intake might exist in patients with 
chronic conditions, such as therapy-related factors, condi-
tion-related factors, patient-related factors, socio-economic 
factors, and health system-related factors.18–21 EMF pro-
vides the opportunity to identify such barriers to adequate 
medication intake, thereby anticipating the large (intra- 
and interpatient) variety over time. The barriers identified 
during these feedback conversations can subsequently act 
as targets for intervening for individual patients.14 In the 
early course of RA, methotrexate is considered to be an 
excellent candidate to improve medication adherence and 
clinical outcomes in the long term.8 Randomized con-
trolled trials on the effectiveness of EMF on medication 
adherence and clinical outcomes in patients with early RA 
are, however, lacking.12,14
Therefore, the primary objective of this study was to 
examine the effectiveness of providing EMF in standard 
care for patients with early RA, using methotrexate, in 
improving medication adherence compared to standard 
care without EMF. The secondary objective was to exam-
ine the effectiveness of the intervention on patients’ dis-
ease activity, health status, beliefs about medicines, and 
time to first anti-TNFα prescription.
Methods
The CONSORT (Consolidated Standards of Reporting 
Trials) statement and EMERGE (ESPACOMP 
Medication Adherence Reporting Guideline) were used 
as guidance for adequate reporting in this study (see 
Appendix A1).22,23
Trial Design
This open-label, randomized clinical trial assessed the 
effectiveness of providing EMF embedded in standard 
care for patients with early RA (Netherlands Trial 
Register: Trial NL4532 (NTR4667)). This study was con-
ducted according to the ethical principles for medical 
research as stated in the Declaration of Helsinki (64th 
WMA General Assembly, Fortaleza, Brazil, 2013). The 
research protocol was submitted for consideration, com-
ment, guidance and approval to the Medical Research 
Ethics Committee (MREC) of Arnhem-Nijmegen before 
the study began. The MREC of Arnhem-Nijmegen waived 
official ethical approval (file number: 2014–137) and 
assessed the trial as not being subject to the Medical 
Research Involving Human Subjects Act (WMO). 
Providing electronic monitoring feedback in addition to 
standard care was not considered an infringement of the 
physical and/or psychological integrity of the subject.
Participants and Selection Procedures
Patients were recruited on two sites of the Sint 
Maartenskliniek (Nijmegen and Boxmeer) in the 
Netherlands. All consecutive patients who fulfilled the fol-
lowing inclusion criteria were eligible to participate in this 
study: (1) a (working) diagnosis of early RA (≤ one year) by 
a rheumatologist, (2) currently using oral or subcutaneous 
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methotrexate, (3) aged ≥18 years, (4) sufficient proficiency 
in the Dutch language, (5) no large cognitive limitations, (6) 
no assistance in taking drugs (ie home care or pill boxes), 
and (7) a life expectancy of at least 12 months given the 
one-year follow-up. A first selection was made by a local 
researcher who screened for eligibility based on the dispen-
sing data of the outpatient pharmacy of the Sint 
Maartenskliniek. For each patient using methotrexate, the 
(working) diagnosis was checked in their medical file or 
verified by their rheumatologist. Subsequently, after receiv-
ing permission from the treating healthcare professional, 
written information with an informed consent form and 
return envelope were sent to all eligible patients on behalf 
of the research team. An independent rheumatologist (ie not 
a member of the research team) was available to discuss this 
information. After one week, the researcher contacted these 
patients by telephone to explore their willingness to parti-
cipate in this study, to check for additional inclusion criteria, 
and to answer questions regarding this study. After a patient 
agreed to participate in this study, a research appointment 
during their next visit to the Sint Maartenskliniek was 
planned to facilitate their signing of the informed consent 
form and perform baseline measurements.
Study Arms
Intervention Arm
During the 12-month study period, patients allocated to the 
intervention arm received their methotrexate packaged in 
an electronic device to provide them with electronic mon-
itoring feedback. In the case of discontinuation of metho-
trexate, patients left the study. After inclusion of 62 
patients, medication blisters (MediccineTM system, 
Confrérie Clinique) were replaced by Medication Event 
Monitoring Systems (MEMS, Aardex®) due to quality 
issues related to the usability of the blisters.
Patients in the intervention arm were provided with 
EMF before each regular consultation (on average, two 
times during a 12-month period) with the rheumatologist. 
The intervention providers (N=6, all pharmacists, 66.7% 
female) completed training in motivational interviewing 
(ie at least one full day's training) to master the basic 
motivational interviewing techniques and to practice the 
communication strategy based on a semi-structured con-
versation model (see Appendix A2 and Figure A2).24,25 
This model was used as basis for an open, patient-tailored 
and non-judgmental conversation between patients and 
trained pharmacists in which the following topics were 
discussed: (recognition of their own) medication-taking 
behavior based on electronic device usage, practical bar-
riers, perceptual barriers (eg concern beliefs about the 
prescribed medication and beliefs related to medication 
necessity), information needs, implementation in daily 
life, and goal setting.
Control Arm
Patients in the control arm received standard care (ie 
a consultation with the pharmacy consultant without the 
use of electronic monitors and EMF before each visit to 
the rheumatologist). During this consultation the following 
topics were discussed: actual medication use, possible 
side-effects, and medication-related issues.
Study Outcomes
The primary study outcome was to identify the difference 
in proportion of non-adherent (taking compliance ≤80%) 
patients with RA after one year between the intervention 
arm and the usual care arm, assessed with the validated 
Compliance Questionnaire on Rheumatology (CQR).26,27 
Secondary outcomes were to record time to first anti- 
TNFα (bDMARD) prescription, proportion of patients on 
anti-TNFα therapy after one year, patients' health status 
after one year, beliefs about medicines after one year, and 
mean disease activity (ie DAS28-CRP) after one year.28–30
Sample Size
Previous research revealed that 35% of patients with RA 
using a DMARD did not adhere to their treatment (taking 
compliance ≤80%).31 Assuming that half of these non- 
adherent patients became adherent after receiving EMF, 
we expected that 65% of the patients in the usual care arm 
and 83% of the patients in the intervention arm would be 
adherent. A sample of 84 patients per study arm (ie study 
sample size = 168) was required to detect this difference of 
18% between the intervention and control arm with 
a power of 80% and alpha=0.05, allowing for a 10% loss 
to follow-up.
Randomization and Blinding
Randomization was conducted by an independent research 
assistant using a computer-generated randomization list (ie 
generated with a random allocation procedure with a 1:1 
allocation ratio). This list was transferred to sheets of 
paper and these sheets of paper were sealed in opaque 
envelopes. With every new patient enrolled in this study, 
a new envelope was opened by the researcher to allocate 
patients to the different study groups. Blinding of patients 
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and researchers was not feasible since electronic drug 
monitors were only used in the intervention arm.
Measurement Instruments
In both study arms, self-reported medication adherence was 
measured with the validated Compliance Questionnaire on 
Rheumatology (CQR, 19 Likert-scaled items, item scores 
ranging from 1 to 4). Self-reported medication adherence 
was operationalized as “taking compliance” calculated with 
the discriminant function for CQR items as described by de 
Klerk et al.27 The critical cut-off score of −0.5849 for taking 
compliance ≤80% was used to identify adherent and non- 
adherent patients.27 The Morisky Medication Adherence 
Scale® (MMAS, 8 items) was used to classify patients as 
low (total score of <6), medium (total score of 6 or 7) and 
high (total score of 8) adherent.26,27,32 Permission to use the 
MMAS-8 was granted by the copyright holder of this ques-
tionnaire, Donald Morisky. Necessity and concern beliefs 
about the prescribed medication were assessed with the 
Beliefs about Medicines Questionnaire Specific (BMQ- 
Specific, 10 Likert-scale items, item scores ranging from 1 
to 5).28,29 These beliefs about medicines were operationa-
lized as sum scale scores for necessity beliefs (range: 5–25), 
as sum scale scores for concern beliefs (range: 5–25), and as 
necessity–concerns differential (NCD) scores.28,29 NCD 
scores were calculated by subtracting the sum of item scores 
for concern beliefs from the sum of item scores for necessity 
beliefs.24,25 A positive NCD indicates that necessity beliefs 
dominate concern beliefs.24,25 Patients' health status was 
routinely assessed with the Health Assessment 
Questionnaire (HAQ, 20 items with 5 dimensions) to provide 
a single index value for health status. For the Health 
Assessment Questionnaire Disability Index (HAQ-DI), the 
highest subcategory score determined the value for each 
category, unless aids or devices were used.30 Patients were 
included in this calculation only if at least six of the eight 
categories were completed. Averaging these eight category 
scores resulted in the HAQ-DI (range: 0–3), with higher 
scores indicating more disability (category 0–1: mild to 
moderate disability, 1–2: moderate to severe disability, 2–3: 
severe to very severe disability).30 Disease activity was rou-
tinely assessed with the DAS28-CRP.1,30 The behavior 
change counselling index (BECCI, 11 Likert-scale items 
ranging from 0 “not at all” to 4 ”to a great extent”) and 
a quality assessment form (see Appendix A3) based on our 
semi-structured conversation model were used to test for 
intervention fidelity and to measure a practitioner’s compe-
tence in behavior change counselling (ie more 
comprehensive than brief advice but less extensive than 
applying motivational interviewing during a brief 
consultation).33 For the BECCI data, an overall mean “prac-
titioner BECCI score” was calculated by adding up the 
individual scores of the applicable items divided by that 
number of items. The overall mean practitioner BECCI 
score corresponds with the points on the Likert scales: 0 
(not at all), 1 (minimally), 2 (to some extent), 3 (a good 
deal), and 4 (to a great extent).33
Data Collection Procedures
At baseline, the following patient and clinical characteristics 
were extracted from patients' medical files by the local 
researcher: age, sex, disease duration, medication use, 
comorbidities, and serology (ie anti-CCP). Disease activity 
was routinely assessed with the DAS28-CRP every three 
months in the first year after diagnosis as part of standard 
care in the Sint Maartenskliniek. Patients were asked to 
complete hardcopy questionnaires concerning beliefs about 
medicines and self-reported medication adherence at base-
line and after 12 months. The first questionnaire was com-
pleted during the first research appointment, whereas the 
hardcopy questionnaire after 12 months was sent to all 
participants with an instruction to return this questionnaire 
in the return envelope. Non-response to questionnaires was 
reduced by using one written reminder and subsequently an 
additional telephone call. Persistence with methotrexate and 
reasons for discontinuation with methotrexate were regis-
tered during the follow-up period of the study. See Figure 1 
for an overview of the study design. Intervention fidelity 
was assessed by audio-recording a random set of 10% of 
the consultations with the intervention providers. These 
audio-recordings were independently assessed by 
a researcher and a research assistant (see Appendix A3) 
on topics that had to be discussed according to the inter-
vention protocol (ie methotrexate use over the past months, 
necessity beliefs, concern beliefs, implementation of meth-
otrexate’s dosing regime in daily life, and needs for addi-
tional information), and on the application of the 
motivational interviewing techniques (ie BECCI practi-
tioner’s score).24 On whose initiative these topics were 
discussed fell outside the remit of this study.
Statistical Methods
Statistical analyses were performed using STATA version 
13.1. Descriptive statistics were used to describe patient 
and disease characteristics. P-values of ≤0.05 were con-
sidered statistically significant.
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Two sample t-tests and two sample tests of proportions 
were performed to test for equality of means or propor-
tions between study arms after one-year follow-up, respec-
tively. Non-normally distributed data were presented as 
medians with interquartile ranges (p=25 to p=75). Two- 
sample Wilcoxon rank-sum tests were performed to test 
for differences in medians between study arms. Mixed- 
model procedures with intention-to-treat approach were 
planned for the main outcomes in this study. Between- 
group differences on methotrexate discontinuation and 
time to initiating a bDMARD were visualized with 
Kaplan–Meier time-to-event curves and tested with log 
rank testing.
Patient and Public Involvement
Two patient research partners were involved in the design 
phase of the intervention and the study. These patient 
research partners were updated annually about the pro-
gress of the study.
Results
Study Sample Characteristics
Patients were recruited between August 6, 2014 and 
June 8, 2018 on two sites of the Sint Maartenskliniek 
(Nijmegen and Boxmeer) in the Netherlands. Of the 367 
initially invited eligible patients, 93 were willing to parti-
cipate in this study (response rate: 25.3%; see Figure 2). 
Due to exceeding the scheduled period for patient recruit-
ment (ie 47 months instead of 18 months) and lack of 
financial resources, this RCT ended before achieving the 
calculated sample size.
Among the 93 participating patients with RA, 65.6% 
was female. Their mean age was 58.9 years (SD=13.7), 
and 69.9% met the ACR/EULAR 2010 RA classification 
criteria at the time of inclusion (see Table 1 for all patient 
characteristics at baseline). The majority of the study 
participants (71.0%) administered methotrexate as subcu-
taneous injection and two study participants allocated to 
the intervention arm used biologic DMARDs at time of 
inclusion. Overall, no relevant differences were found in 
baseline characteristics between the intervention arm and 
the control arm. Regarding attrition rates, 34 patients 
(36.6%) did not complete the 12-month follow-up period 
of the study. Main reasons for not completing the 12- 
month follow-up period were discontinuation of metho-
trexate (ie due to side-effects and/or inefficacy of metho-
trexate) (N=24), issues related to comorbidities (N=5), and 
study-related issues (N=4). This resulted in a large propor-
tion of non-random missing data at 12-month follow-up.
Primary and Secondary Study Outcomes
The intervention protocol could only be followed when 
patients were receiving active treatment with methotrex-
ate. Due to the large proportion of patients who discon-
tinued methotrexate (ie according to the treatment 
protocol), we were confronted with a large proportion of 
missing values (not at random) on the primary endpoint at 
12 months. Therefore, we decided to deviate from the 
planned mixed-model procedures. Instead, all available 
data were presented as descriptive statistics on the primary 
Regular visit to the rheumatologist


















































Figure 1 Study design of the RCT: electronic monitoring feedback (EMF) versus usual care. 
Abbreviation: PPC, pharmaceutical pre-consultation.
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and secondary study outcomes after 12 months (see 
Table 2).
No significant differences were found between the 
intervention arm and the usual care arm after 12-month 
follow-up for the following variables: proportion of adher-
ent patients measured with the CQR (mean difference: 
1.3%, 95% CI −30.0; 30.0), medication adherence mea-
sured with the MMAS-8® (median sum score: 7 (6–7) and 
7 (6–7), respectively; p=0.27), sum scale scores for neces-
sity beliefs (median: 18 (17–21) and 19 (16–20), 
respectively; p=0.76), sum scale scores for concern beliefs 
(median: 14 (9–17) and 14 (12–17), respectively; p=0.79), 
and necessity concern differential score (median: 4 (2–7) 
and 3 (2–6), respectively; p=0.56). Patients in the inter-
vention arm tended to discontinue methotrexate earlier 
than patients in the usual care arm (median time in 
weeks: 15.7 (9.1–33.6) and 21.9 (19–28.4), respectively; 
p=0.31), whereas the median time to initiate a bDMARD 
tended to be shorter in the usual care arm than in the 
intervention arm (11.9 (5.7–22) and 17 (9.9–40.9), 
Figure 2 Flowchart of study participants. 
Abbreviation: CQR, Compliance Questionnaire on Rheumatology.
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respectively; p=0.55). Figures 3 and 4 visualize time to 
methotrexate discontinuation and time to start with 
a bDMARD between study arms over time. Log rank 
tests for equality of survivor functions showed no signifi-
cant differences between study arms on methotrexate dis-
continuation and initiating bDMARDs (data not shown). 
Sensitivity analyses were avoided due to the small number 
of patients available for subgroup analyses.
Intervention Fidelity
Of all patients allocated to the intervention arm (N=47), 11 
patients (23.4%) received no electronic monitoring feedback 
during the study. This was a result of the high attrition rate of 
study participants due to methotrexate discontinuation, 
together with technical issues related to the electronic cir-
cuits of the MediccineTM medication blisters during the first 
part of the study (ie not able to register blister openings and 
print read-outs). In total, 28 patients (59.6% of the interven-
tion arm) received EMF based on MEMS devices, whereas 
19 patients received at least one MediccineTM medication 
blister during the study. Audio-recordings (N=27) of the 
electronic monitoring feedback sessions were assessed by 
a researcher and research assistant. The mean duration of 
providing EMF was 8.3 minutes (SD=6.3) and electronically 
monitored adherence data were available for 25 patients. 
Two patients received no EMF due to the absence of elec-
tronically monitored adherence data. The proportion of 
topics discussed during the EMF consultations was as fol-
lows: concern beliefs (N=13, 48.1%), necessity beliefs 
(N=5, 18.5%), implementation of medication regimen in 
daily life (N=21, 77.8%), and patient’s need for additional 
information (N=15, 55.6%). Furthermore, more than half of 
the patients on the audio-recordings (N=15, 55.6%) showed 
irregular medication-intake patterns. The mean practitioner 
BECCI score was 1.6 (SD=0.70), which indicates that the 
trained pharmacists practiced behavior change counselling 
ranged from “minimally” to “to some extent”.
Discussion
Summary of Evidence
This study failed to show the effectiveness of EMF on 
self-reported medication adherence in patients with early 
RA. Negative findings were also found on beliefs about 
medicines, patients' health status, biologic DMARD use 
and disease activity scores after one-year follow-up. It 
cannot be excluded that these findings were impacted by 
the limitations of this study together with the encountered 
barriers for applying EMF in standard care. Therefore, this 
article shares lessons learned regarding feedback on elec-
tronically obtained adherence data as an intervention to 
improve medication adherence and clinical outcomes in 
patients with early RA in standard care. The lessons 
learned from this study relate to the following themes: 
(1) attrition, (2) drug survival, (3) intervention fidelity, 
(4) intervention uptake, and (5) technical issues.
Review of Findings
Several issues related to the intervention prevented draw-
ing valid conclusions on the effectiveness of EMF in this 
patient population. Therefore, we conclude it is not 
Table 1 Baseline Characteristics of Study Participants for Both 
Study Arms
Patient Characteristics Intervention Usual Care
(N=47) (N=46)
Age (years), mean (SD) 58.1 (13.6) 59.9 (13.9)
Female, N (%) 33 (70.2) 28 (60.9)
Disease-related characteristics
Anti-CCP status positive, n (%) 22 (46.8) 25 (54.3)
RA according to ACR-2010 
criteria, n (%)
34 (72.3) 31 (67.4)
Standard disability index score 
measured with HAQ, median 
(IQR)
0.25 (0–0.75) 0.375 
(0.125–1)
DAS28-CRP, mean (SD) 2.5 (1.1) 2.7 (1.1)
Treatment characteristics
Methotrexate, oral, n (%) 17 (36.2) 10 (21.7)
Methotrexate, subcutaneous, 
n (%)
30 (63.8) 36 (78.3)
Hydroxychloroquine, n (%) 33 (70.2) 34 (73.9)
Biologic DMARD (yes), n (%) 2 (4.3) 0 (0.0)
Beliefs about medicines
Sum scale score for necessity 
beliefs, median (ICR)
18 (16–21) 19 (18–21)
Sum scale score for concern 
beliefs, median (ICR)
14.5 (10–17) 15.5 (12–17)
Self-reported adherence to medication
Proportion of adherent patients 
measured with CQR, n (%)
36 (81.8) 35 (77.8)
Proportion of low adherence 
measured with MMAS-8®, n (%)
8 (27.6) 9 (27.3)
Proportion of medium adherence 
measured with MMAS-8®, n (%)
21 (72.4) 24 (72.7)
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justified to compare the findings of this study on the 
effectiveness of EMF with findings from previous 
research.12–14 Nevertheless, previous work indicated that 
EMF might be a promising intervention to enhance med-
ication adherence in adult patients.13–15 It is, therefore, 
possible that EMF might be effective in improving medi-
cation adherence and clinical outcomes in patients with 
early RA, but this was not detected due to methodological 
issues. Statistical power issues (ie due to the small sample 
size of this study together with the high attrition rates after 
one-year follow-up) have complicated the possibility of 
detecting an intervention effect in this study. Similar diffi-
culties were, however, encountered in previous adherence 
research (eg small sample sizes, high attrition rates, lim-
ited protocol adherence), thereby also recognizing the 
challenge of recruiting a representative study sample.14,34 
Nevertheless, several methodological considerations are 
extensively discussed below to share the lessons learned 
from this study rather than concluding that this study does 
not contribute to the body of knowledge.
Strengths, Limitations and Lessons 
Learned
The key strengths of this study included a randomized 
controlled study design, the incorporation of disease out-
comes besides adherence outcomes, the use of validated 
questionnaires (ie CQR and MMAS-8®) to assess medica-
tion adherence, and the long-term follow-up period since 
intervention effects on clinical outcomes often manifest 
over time. Previous work indicated that adherence rates 
of patients in the usual care arm were influenced by 
(regular) assessment of adherence to medication (ie due 
to awareness of being monitored).35 Therefore, the authors 
decided to measure adherence to medication at baseline 
and 12-month follow-up only. Nevertheless, there is an 
ongoing debate on what measurement instruments and 
definitions for adherence outcomes should be used to 
accurately capture patients’ medication-taking 
behavior.4,17,36–39
The first lesson learned relates to attrition rate after 
randomization in this RCT together with drug survival. 
Although attrition rates did not significantly differ between 
study arms, the overall attrition rate contributed to statis-
tical power issues for detecting an intervention effect. Low 
drug survival (ie due to methotrexate discontinuation) 
together with the relatively long follow-up period were 
the main reasons for the high attrition rate. The authors, 
however, did not take low drug survival into account in the 
power calculation.40 Therefore, one of the lessons learned 
is that data on drug survival might be more relevant to 
include in power calculations than data on loss to follow- 
up. Furthermore, critically reviewing the planned study 
duration on feasibility and relevance for the study out-
comes is recommended.
The next lessons learned relate to barriers/difficulties 
for applying EMF in standard care in patients with early 
RA. Regarding intervention fidelity, we found that the 
degree to which the trained pharmacists practiced behavior 
Table 2 Study Results of the RCT: Effectiveness of Electronic Monitoring Feedback (EMF) in Standard Care
Intervention Usual Care p-value
Primary study outcome at 12 months
Proportion of adherent patients measured with CQR, n (%) 12 (60.0) 19 (61.3) 0.93
Secondary outcomes at 12 months
Sum scale score for MMAS-8, median (IQR) 7 (6–7) 7 (6–7) 0.27
Sum scale score for necessity beliefs, median (IQR) 18 (17–21) 19 (16–20) 0.76
Sum scale score for concern beliefs, median (IQR) 14 (9–17) 14 (12–17) 0.79
Necessity differential score, median (IQR) 4 (2–7) 3 (2–6) 0.56
Clinical outcomes at 12 months
Time to methotrexate discontinuation (weeks), median (IQR) 15.7 (9.1–33.6) 21.9 (19–28.4) 0.31
Time to TNF-alpha inhibitors (weeks), median (IQR) 17 (9.9–40.9) 11.9 (5.7–22) 0.55
Proportion of patients on TNF-alpha inhibitors, n (%) 11 (23.4) 11 (23.9) 0.95
Standard disability index score measured with HAQ, median (IQR) 0 (0–0.25) 0.125 (0–0.625) 0.25
DAS28-CRP, median (IQR) 1.99 (1.31–2.61) 1.64 (1.24–2) 0.27
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change counselling ranged from “minimally” to “to some 
extent” and the extent to which topics were discussed 
varied considerably. However, EMF is a tailored interven-
tion and scoring the audio-recordings might, therefore, be 
too strict an approach upon which to decide whether the 
intervention protocol was (in)sufficiently followed. For 
future research, providing personal feedback on a regular 
basis to intervention providers, thereby using their own 
audio-recordings, is recommended. This makes it possible 
to intervene in case intervention providers deviate from the 
intervention protocol. Contamination of the intervention 
effect between study arms might also have occurred due 
to randomization on the level of patients instead of health-
care professionals. Most patients assigned to the usual care 
arm, however, received standard care from a pharmacy 
consultant instead of trained pharmacists.
Regarding intervention uptake in clinical practice, it is 
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Figure 4 Kaplan–Meier survival estimates: initiation of bDMARDs in both study arms.
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preferences in the early stage of the disease.41 Patients 
included in this study were dealing with the ongoing 
process of accepting their new diagnosis and implement-
ing chronic medication use in daily life. Several factors 
might have contributed to the low degree of patients’ 
willingness to participate in this study.41 Therefore, we 
recommend conducting a pilot study before starting 
an RCT to provide insight into: (1) reasons for unwilling-
ness to participate in a study, (2) inclusion rate, (3) prac-
tical issues, and (4) technical issues. Conducting 
a qualitative interview study on patients who refused to 
participate in this study might also provide in-depth infor-
mation regarding reasons for unwillingness to participate 
in adherence trials. This information can be relevant for 
designing future adherence trials and to assess whether the 
study sample will be representative of the general popula-
tion. Furthermore, it cannot be excluded that the technical 
issues encountered with the medication blisters might 
have negatively influenced patients’ engagement with 
treatment adherence. This might have strengthened the 
absence of an intervention effect. Therefore, we endorse 
performing pre-tests with innovative electronic devices to 
avoid technical issues during the conduct of the study.
Generalizability
The proportion of patients with “low adherence” based on 
the MMAS-8 at baseline was significantly lower than 
proportions of patients with “low adherence” reported in 
previous work.42 Theoretically, this might indicate that 
patients enrolled in this study may be less able to show 
improvements on adherence outcomes compared with less 
adherent patients with RA. Considering the low mean 
disease activity scores at baseline for both study arms, 
the low response rate, and the large number of patients 
who discontinued methotrexate before inclusion, we con-
clude that selection bias prior to trial entry is likely. In 
addition, the high quality of standard care in the Sint 
Maartenskliniek might have decreased the contrast in 
interventions between study arms (ie standard care 
might not be standard care per definition). Also, the 
large number of study participants who were administered 
methotrexate subcutaneously compared to oral adminis-
tration due to local treatment protocols might have limited 
the generalizability of the results. However, no differ-
ences were found on gender and mean age between 
patients who participated in this trial and patients who 
refused to participate in this study (female: 65.6% versus 
63.5%; mean age: 58.9 years versus 57.9 years, 
respectively).
Conclusion
In conclusion, no evidence for the effectiveness of EMF 
on improving medication adherence and clinical outcomes 
was found in patients with early RA. Although several 
lessons learned can be drawn from this RCT, this study 
underlines the challenges that have to be overcome when 
conducting a behavioral intervention in a study setting. We 
therefore recommend learning from the lessons described 
in this article when designing an adherence-improving 
intervention, such as EMF, for patients with RA. 
Implementing EMF in clinical practice is not yet recom-
mended in patients with (early) RA.
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